Figure 5.

(A) Percentage of animals with change in tumor volume. On comparison of pre and post-treatment MRIs, 78.9% of placebo animals demonstrated an increase in tumor volume, and 21.1% had stable disease. Following treatment with abemaciclib, 81.8% of animals demonstrated a decrease in tumor volume, and 18.2% had stable disease. RECIST criteria of <20% increase or <30% decrease in volume were classified as stable. (B) Mean percent change in tumor volume. Following treatment, animals in the placebo arm demonstrated a mean increase in tumor volume of 133.5%. Conversely, animals treated with abemaciclib revealed a mean decrease in tumor volume by 65.5% (p<0.01).